Inflammatix Ships TriVerity™ Test Cartridges and Myrna™ Instruments to the U.S. Military
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) purchases TriVerity Test System to evaluate for use in the field
Inflammatix receives an initial $1.2 million to cover the first phase of system evaluation, with future phase options worth up to $20.8 million
SUNNYVALE, Calif., March 25, 2025 /PRNewswire/ — Inflammatix, a pioneering molecular diagnostics company, today announced the shipment of TriVerity™ cartridges and Myrna™ instruments to the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to facilitate the differentiation of bacterial infections, viral infections, and non-infectious illness. In the first phase of its agreement with Inflammatix, the JPEO-CBRND, which manages the acquisition, fielding and sustainment of chemical, biological, radiological, and nuclear (CBRN) defense capabilities to the joint force, will assess the viability of TriVerity cartridges and Myrna™ instruments for field use. The initial shipment, for which Inflammatix is to receive more than $1.2 million, is part of a JPEO-CBRND contract worth up to $20.8 million if all options are exercised.
